The selective antagonist of the AT1 receptor, losartan, prevents the development of ARDS triggered by lung bacterial infection through suppressing the activation of neutrophils by N-formylmethionyl-leucyl-phenylalanine (fMLP) [98]. Here, AGTR1 is linked to acute respiratory distress syndrome.